ZENCITY
7.12.2021 15:18:12 CET | Business Wire | Press release
Zencity, the leading global community engagement technology platform for local governments, announced the acquisition of cutting edge digital engagement startup Civil Space, based in Vancouver, Canada. The deal immediately adds to Zencity’s powerful suite the capability to create and capture deep, meaningful, equitable, two-way conversations between governments and their residents.
With its acquisition of Civil Space, Zencity emerges as the most effective, inclusive and wide-reaching community engagement platform available for local governments, built around two core principles:
- Lowering the barriers to participation by meeting residents where they are and hearing many more voices; and
- Making it easier for governments to turn the resulting, broadened community input into action.
The combination of Zencity’s analysis of broad community input with Civil Space’s direct engagement platform will enable local leaders to further enhance the feedback they are leveraging. The information will be presented to local leaders using sophisticated technology and an integrated approach to create a 360 degree feedback process never before available to local governments.
“We are excited to deepen our ability to support local government by being more inclusive, collaborative and responsive. The new capabilities that will be added to the Zencity platform today from Civil Space round out our offering, making sure we can answer our partners' needs by enabling local leaders to easily solicit, measure and incorporate the public’s feedback into every decision they make,” said Eyal Feder-Levy, CEO, Zencity .
“Adding Civil Space's rich community engagement capabilities to the innovative approach that Zencity has taken disrupts how decisions can be made by local governments around the world. We are excited to be offering governments and their constituents the solutions they need to ensure that every community has a voice, resulting in increased responsiveness and trust between local governments and the people they serve,” said Tim Booker, CEO, Civil Space.
Tim Booker will join Zencity as Head of Civil Space, and will lead Zencity’s new Vancouver, Canada office. In March of 2021, Zencity acquired Elucd, a technology company based in New York City. The company now serves over 250 local governments, including seven of the ten largest US cities.
About Zencity
Zencity, based in Tel Aviv, Israel, and New York City, is a community insights and analytics platform that provides local government leaders actionable data about their residents’ needs and priorities. As the most comprehensive civic engagement solution for local governments on the market, Zencity offers leaders insights from resident feedback through the analysis of millions of pieces of anonymized and aggregated data points alongside continuous, community-based polling. More than 250 local government agencies across the United States, Canada, Australia, the UK and Israel depend on Zencity to take civic engagement to the next level in order to inform decision-making, build trust, measure progress, and ensure the efficient allocation of resources. Visit https://zencity.io for more information.
About Civil Space:
Civil Space is a Vancouver, Canada based digital engagement platform for communities and their leaders to co-create sustainable futures together. Using Civil Space, local government leaders can surface real needs, understand diverse citizen priorities and collaborate on key initiatives through an inclusive, accessible platform designed for education and equity. Visit https://civilspace.io for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005729/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
